IXICO wins £1.5 million of Alzheimer’s imaging and biomarker work
IXICO ($IXI) secured two Alzheimer’s-related contracts with a combined value of approximately £1.5 million. One covers neuroimaging management and analysis for a biotechnology client’s Phase 2b study, with revenue expected over roughly three years. The other extends work for an international life-sciences diagnostics customer, using IXICO’s imaging platform to support validation and regulatory submissions for a blood-based Alzheimer’s biomarker test. Revenue from the diagnostics extension is exp
0